Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Hassan Dorani"'
Autor:
Peter A. Johansson, Folke Sjöberg, Maria Wollbratt, Ensio Norjavaara, Hassan Dorani, Maria Heijer, Hans Ericsson
Publikováno v:
Diabetes Research and Clinical Practice. 98:436-444
To investigate the pharmacodynamics, pharmacokinetics and safety of the glucokinase activator AZD6370 after 1 day of administration under fed and fasted conditions in patients with type 2 diabetes mellitus (T2DM).This was a two-part study. In Part A,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8a70a8ade9befb4e4412fd7e4f8a459
https://doi.org/10.1016/j.diabres.2012.09.025
https://doi.org/10.1016/j.diabres.2012.09.025
Autor:
Ulf Eriksson, Ulrika Logren, Kajs-Marie Schützer, Lis Ohlsson, Troy C. Sarich, Hassan Dorani, Ulrika Wall
Publikováno v:
European Journal of Clinical Pharmacology. 63:571-581
To study the effects of amoxicillin, doxycycline, ciprofloxacin, azithromycin, and cefuroxime on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, which is a substrate for the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c9e654414d361285adfe44532980817
https://doi.org/10.1007/s00228-007-0292-6
https://doi.org/10.1007/s00228-007-0292-6
Autor:
Johan E. Karlsson, Troy C. Sarich, Holger Fritsch, Ulf Eriksson, Lis Olsson, Ulrika Wall, Hassan Dorani, Kajs-Marie Schützer, Kurt-Jürgen Hoffmann
Publikováno v:
Drug Metabolism and Disposition. 34:775-782
A pharmacokinetic interaction between erythromycin and ximelagatran, an oral direct thrombin inhibitor, was demonstrated in this study in healthy volunteers. To investigate possible interaction mechanisms, the effects of erythromycin on active transp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be620d2af941f54dbad77f9451e8fc79
https://doi.org/10.1124/dmd.105.008607
https://doi.org/10.1124/dmd.105.008607
Autor:
Hassan Dorani, Kajs-Marie Schützer, Ulrika Wall, Ulf Eriksson, Troy C. Sarich, Lis Ohlsson, Inge Kalies
Publikováno v:
Journal of clinical pharmacology. 44(8)
In this randomized, 2-way crossover study, the potential for interaction was investigated between atorvastatin and ximelagatran, an oral direct thrombin inhibitor. Healthy female and male volunteers (n = 16) received atorvastatin 40 mg as a single or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::712a3c50e0a66be3140dae5b6057d4bf
https://pubmed.ncbi.nlm.nih.gov/15286097
https://pubmed.ncbi.nlm.nih.gov/15286097
Publikováno v:
Clinical Pharmacology & Therapeutics. 77:P46-P46
Background The effects of amoxicillin, doxycycline, and ciprofloxacin on the pharmacokinetics and pharmacodynamics of melagatran after administration of oral ximelagatran were evaluated. Methods Healthy volunteers (n=48) sequentially received two tre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f0001a9dbb712a07aa497c4e02be5125
https://doi.org/10.1016/j.clpt.2004.12.069
https://doi.org/10.1016/j.clpt.2004.12.069
Publikováno v:
Clinical Pharmacology & Therapeutics. 77:P83-P83
Background Ximelagatran is bioconverted to its active form melagatran. It has a low potential for drug interactions as its metabolism is independent of CYP450 enzymes. Methods Healthy volunteers (n=32) received ximelagatran 36 mg as a single oral dos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::290ac4482e45900ba82ff175f50f9dd2
https://doi.org/10.1016/j.clpt.2004.12.211
https://doi.org/10.1016/j.clpt.2004.12.211
Autor:
Troy C. Sarich, Kajs-Marie Schützer, Hassan Dorani, Ulrika Wall, Inge Kalies, Lis Ohlsson, Ulf G. Eriksson
Publikováno v:
Journal of Clinical Pharmacology; Aug2004, Vol. 44 Issue 8, p928-934, 7p